Sotac Pharmaceuticals Ltd. (SOTAC)
SME CapPharma stocks · SME cap · NSE
Sotac Pharmaceuticals Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is acceptable, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Bad · 2/100PAT 0% YoY · margin compression · Rev +15% YoY · +62% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹60 Cr | +15.4% | +62.2% |
| EBITDA | ₹10 Cr | -16.7% | +150.0% |
| Operating margin | 17.0% | -900 bps | +700 bps |
| PAT | ₹3 Cr | +0.0% | +50.0% |
| PAT margin | 5.0% | -777 bps | -41 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Issuer presentation review pending
Sotac Pharmaceuticals Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
Trend score and candlestick chart
45NeutralSMA20 -7.7% / mo · MACD − · near 52W low · sector +2.2pp vs Nifty (3M)
Technical chart
SOTACdaily · 1Y · AUTO-24.2%Daily technical trend read
Bearish setupTrend is weak — long-term trend unclear. RSI 32.
- SMA20 falling (~8.4% over last month) — short-term momentum negative.
- RSI(14) at 32 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 54 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 54 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- FCF yield is supportive at 10.1%.
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 61.7%.
Main drags
- Penalty bucket subtracts 7 points.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 45th percentile of the scored universe and 33rd percentile within Pharma. Main check: results consistency is weak at 43/100.
Healthy Trust Lite: Promoter holding is 72.9%. Key concern: Only 1 years of positive FCF.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 33rd pctile, median 70 · SME: 56th pctile, median 64
0 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 72.9%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 10.1%.
- ▸3/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Only 1 years of positive FCF.
- ▸1/4 latest quarters had positive YoY PAT growth.
- ▸OPM spread across recent quarters is 18%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 17.20
- P/B
- 1.69
- EV/EBITDA
- 5.98
- Market Cap
- 99.50Cr
Profitability
- ROE
- 10.30%
- ROCE
- 12.60%
- ROA
- 4.51%
- Dividend Y
- 0.11%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 35.00%
- Revenue 3Y
- 10.00%
- EPS 3Y
- 31.00%
Balance Sheet
- Debt/Equity
- 0.64
- Interest Coverage
- 4.50×
- Altman Z
- 2.68
- Book Value
- 53.30
Cash Flow
- FCF Yield
- 10.05%
- FCF Positive Y
- 1/5
- OCF
- 17.00 Cr
- EPS TTM
- 5.22
Shareholding
- Promoter Hold
- 72.85%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 7%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.